Metabolic reprograming confers tamoxifen resistance in breast cancer

2021/07/28 by Alok Mishra, Anshuman Srivastava, Ankit Pateriya +4 · 78 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Biology #Breast cancer #Cancer #Cancer cell #Cancer research #Cancer, Hypoxia, and Metabolism #Cancer, Lipids, and Metabolism #Estrogen receptor #Internal medicine #Medicine #Metabolism, Diabetes, and Cancer #Metastasis #Oncology #Tamoxifen

paper · doi:10.1016/j.cbi.2021.109602

published in Chemico-Biological Interactions 347, 109602 (Elsevier BV)

openalex publication_date 2021/07/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Citations

• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
• Breast cancer statistics, 2019

Cited by

• Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α. [europepmc]
• The Obesity-Related Metabolic Gene HSD17B8 Protects Against Breast Cancer: High RNA/Protein Expression Means a Better Prognosis. [europepmc]
• The Functions of TRIM56 in Antiviral Innate Immunity and Tumorigenesis. [europepmc]
• LPCAT1 is transcriptionally regulated by FOXA1 to promote breast cancer progression and paclitaxel resistance. [europepmc]
• Identification of circRNA-miRNA-mRNA network in luminal breast cancers by integrated analysis of microarray datasets. [europepmc]
• circRNAs in drug resistance of breast cancer. [europepmc]
• H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy. [europepmc]
• Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer. [europepmc]
• Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies. [europepmc]
• Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications. [europepmc]
• Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-Brain Barrier Models. [europepmc]
• Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA. [europepmc]
• Comparative metabolomics of MCF-7 and MCF-7/TAMR identifies potential metabolic pathways in tamoxifen resistant breast cancer cells. [europepmc]
• MCL restrained ROS/AKT/ASAH1 pathway to therapy tamoxifen resistance breast cancer by stabilizing NRF2. [europepmc]
• The GPR30 Receptor Is Involved in IL-6-Induced Metastatic Properties of MCF-7 Luminal Breast Cancer Cells. [europepmc]
• PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells. [europepmc]
• In Vivo HOXB7 Gene Silencing and Cotreatment with Tamoxifen for Luminal A Breast Cancer Therapy. [europepmc]
• Soy Isoflavone Genistein Enhances Tamoxifen Sensitivity in Breast Cancer via microRNA and Glucose Metabolism Modulation. [europepmc]
• From Chemical Composition to Antiproliferative Effects Through In Vitro Studies: Honey, an Ancient and Modern Hot Topic Remedy. [europepmc]
• BMI-dependent prognostic role of EEF1G in breast cancer: A 15-year follow-up of the Guangzhou Breast Cancer Cohort Study. [europepmc]
• ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer. [europepmc]
• Breast Cancer Progression and Its Theranostic Management via Folate-Directed Targeting of Glycoprotein Receptor. [europepmc]
• Lipid Metabolism and Breast Cancer Therapy: An Integrative Literature Review. [europepmc]
• ERα-Independent Activity of Tamoxifen-Based Transition Metal Hybrids in Triple-Negative Breast Cancer Models In Vitro and In Vivo. [europepmc]
• Applications of Metabolomics to the Clinical Management of Breast Cancer: New Perspectives for Diagnosis, Treatment and Prognosis [europepmc]